Imbruvica

Chemical Nameibrutinib
Dosage FormCapsule (oral; 70 mg,140 mg); Tablet (oral; 140 mg, 280 mg, 420 mg, 560 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyPharmacyclics
Approval Year2013

Indication

  • For the treatment of adult patients with mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
  • For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) in adult patients.
  • For the treatment of adult patients with lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion in adult patients.
  • For the treatment of adult patients with Waldenström’s macroglobulinemia (WM) in adult patients.
  • For the treatment of adult patients with marginal zone lymphoma (MZL) in adult patients who require systemic therapy and have received at least one prior anti-CD20-based therapy.
  • For the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Last updated on 6/23/2022

More on this drug: Clinical Trials

Document TitleYearSource
Imbruvica (ibrutinib) Prescribing Information.2022Pharmacyclics LLC, Sunnyvale CA

Have we missed a study, or would you like to comment on a study?